New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
October 5, 2012
10:38 EDTREGN, RHHBYCompounding linked to new round of contamination, NY Times says
A deadly meningitis outbreak is being linked to a steroid drug being contaminated by fungus at the New England Compounding Center, according to a New York Times report. The report noted that the center has a history of problems, including past FDA warnings cautioning it against opening sterile vials of Roche's (RHHBY) Avastin. The Fly notes that Regeneron Pharmaceuticals' (REGN) Eylea competes with Avastin as a treatment for Wet Macular Degeneration. Reference Link
News For RHHBY;REGN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 27, 2015
19:14 EDTREGNExpress Scripts to cover both Repatha, Praluent for now, Bloomberg says
Subscribe for More Information
07:51 EDTRHHBYRoche catching up fast to Bristol-Myers in immuno-oncology, says Jefferies
Subscribe for More Information
August 25, 2015
08:21 EDTREGNRegeneron has multiple catalysts, says Leerink
Subscribe for More Information
August 24, 2015
12:01 EDTRHHBYRoche buys nucleic acid purification technology from Lumora
Roche has signed a definitive asset purchase agreement with Lumora for products associated with the patent-protected Heat Elution technology for nucleic acid purification of multiple sample types including challenging formalin-fixed paraffin-embedded tumor samples. Roche plans to explore integrating this technology into its sequencing workflow solution.
07:23 EDTREGNRegeneron should be bought on pullbacks, says RBC Capital
Subscribe for More Information
August 23, 2015
12:35 EDTREGN, RHHBYBiotech firms could see 'billions' in sales from new cancer drugs, Barron's says
Subscribe for More Information
August 21, 2015
09:38 EDTRHHBYUBS global healthcare analysts hold an analyst/industry conference call
Subscribe for More Information
August 17, 2015
06:22 EDTREGNPiper's Tenthoff sees select biotech names outperforming in second half
Piper Jaffray analyst Edward Tenthoff expects drug launches, clinical data read-outs and potential partnerships to drive outperformance for select biotech names in the second half of 2015. Despite some recent profit-taking, 2015 has been another strong year for biotech stocks, Tenthoff tells investors in a research note. Names with important second half of the year catalysts include Vertex (VRTX), Regeneron (REGN), Seattle Genetics (SGEN), Exelixis (EXEL), Sarepta (SRPT), Novavax (NVAX), Arrowhead (ARWR), Array BioPharma (ARRY), Alnylam (ALNY), Genocea (GNCA), CymaBay (CBAY), Idera Pharmaceuticals (IDRA), Vitae Pharmaceuticals (VTAE).
05:14 EDTRHHBYGenentech reports atezolizumab pivotal Phase II study met primary endpoint
Subscribe for More Information
August 13, 2015
06:16 EDTRHHBYRoche acquires GeneWEAVE to bolster offerings in microbiology diagnostics
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use